Clinical use of intravenous immunoglobulin in juvenile dermatomyositis: indications, treatment course, and clinical outcomes
IVIG appears to be a safe and effective treatment option for JDM, particularly in refractory or skin-predominant disease. Although causal inferences are limited by the retrospective design and the absence of a control group, these real-world findings support the inclusion of IVIG in an individualized treatment approach.
Authors
- Betül Sözeri (ORCID: https://orcid.org/0000-0002-5079-5644)
- Nuray Aktay Ayaz (ORCID: https://orcid.org/0000-0003-3594-7387)
- Mustafa Çakan (ORCID: https://orcid.org/0000-0002-1034-6406)
- Özlem Akgün (ORCID: https://orcid.org/0000-0001-7216-0562)
- Şeyma Türkmen (ORCID: https://orcid.org/0000-0002-2318-0361)
- Ayşenur Doğru (ORCID: https://orcid.org/0000-0001-8091-8417)
- Gülşah Kavrul Kayaalp (ORCID: https://orcid.org/0000-0001-7490-7076)
- Aslı Dudaklı (ORCID: https://orcid.org/0000-0001-5454-0182)
- Nihal Şahin (ORCID: https://orcid.org/0000-0002-2122-6952)
- Selen Duygu Arık (ORCID: https://orcid.org/0000-0001-7648-1195)
- Bengisu Menentoğlu (ORCID: https://orcid.org/0000-0003-2774-9591)
- Nebahat Zeynep Özaslan (ORCID: https://orcid.org/0000-0003-2641-4140)
- Büşra Başer Taşkın (ORCID: https://orcid.org/0009-0003-5097-4479)
Institutions
- Zeynep Kamil Hospital (TR)
- Ümraniye Eğitim ve Araştırma Hastanesi (TR)
- Kocaeli Üniversitesi (TR)
- Istanbul University (TR)
- Marmara University (TR)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/14712598.2025.2604058
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00